Recommended Starting Dose of Conapzine (Prochlorperazine)
The recommended starting dose of prochlorperazine is 5-10 mg oral or IV for breakthrough antiemetic therapy in adults 1.
Dosing by Clinical Context
For Antiemetic Use (Primary Indication)
The ASCO 2020 antiemetic guideline establishes prochlorperazine as a dopamine receptor antagonist for breakthrough nausea and vomiting, with a starting dose of 5-10 mg oral or IV 1. This applies to:
- Radiation-induced nausea/vomiting: Use as breakthrough therapy, titrating up as needed to maximum of 3-4 administrations daily 1
- Chemotherapy-induced nausea/vomiting: Same dosing parameters apply 1
The guideline evidence is clear and unambiguous—start at 5-10 mg and adjust based on response.
For Vertigo Management
In acute peripheral vertigo, the standard dose is 5 mg three times daily for 5 days 2. This regimen showed 91.1% improvement in clinical response with excellent tolerability in a large prospective study of 1,716 patients 2.
Route of Administration Considerations
- Oral route: Preferred initial approach with 92.1% showing improved clinical response 2
- Intramuscular route: Alternative for patients unable to take oral medication, with 85.5% showing improvement 2
- IV route: Acceptable alternative, though higher doses (0.8 mg/kg IV) have been studied in chemotherapy settings 3
Critical Safety Considerations
Pediatric Use Warning
Do not use in children under 2 years of age 4. In children ≥2 years, prochlorperazine carries significant risks:
- Extrapyramidal symptoms occur in 4-9% of pediatric patients 5
- Sedation occurs in 10% 5
- Serious adverse events including seizures, neuroleptic malignant syndrome, and fatalities have been reported 5
- Crushing tablets is NOT equivalent to liquid formulations—significant harm has occurred when switching from liquid to crushed tablets without dose adjustment 6
Dose-Limiting Toxicities in Adults
At higher IV doses (>0.8 mg/kg), the primary concerns are:
- Hypotension: Dose-limiting at 1.2 mg/kg IV, reversible with fluid loading 3
- Extrapyramidal reactions: Dose-related, with restlessness occurring universally at 1.2 mg/kg 3
- Sedation and dry mouth: More common at higher doses 3
Practical Algorithm
- Start with 5 mg oral or IV for most adult patients requiring antiemetic therapy
- Assess response after first dose (onset typically within 30-60 minutes)
- If inadequate control: Increase to 10 mg per dose
- Maximum frequency: 3-4 administrations daily 1
- For vertigo: Use 5 mg TID as standard regimen 2
The evidence strongly supports starting at the lower end of the 5-10 mg range and titrating upward based on efficacy and tolerability, rather than starting at maximum doses which increase risk of extrapyramidal symptoms and sedation.